GET DAILY SIGNALSCognition Therapeutics (CGTX) Down 7% Over 30 Days as Phase 3 Plans Advance
Key Takeaways
- CGTX shares declined roughly 7% over the last 30 days, moving from about $0.73 to near $0.68 — a modest pullback that reflects a volatile, news-driven clinical-stage biotech rather than a decisive trend reversal.
- The defining catalyst arrived on October 22, 2026, when Cognition announced FDA alignment on key elements of a pivotal Phase 3 trial of zervimesine (CT1812) in dementia with Lewy bodies (DLB).
- Third-quarter 2026 results, reported November 5, showed a narrowed net loss of $4.1 million, or $0.04 per share, with cash of approximately $31.5 million and runway into the fourth quarter of 2027.
- The planned DLB Phase 3 trial remains unfunded, a key overhang that has kept sentiment mixed even as the regulatory path becomes clearer.
- Topline data from the NIA-funded Phase 2 START study in early Alzheimer's disease is expected in the second half of 2027.
- For more detail on valuation and expectations, explore the latest Price Targets, Earnings, and Forecast pages.
- To track quantitative trading signals across the broader market, explore Trending AI Robots.
Market Snapshot for CGTX
Cognition Therapeutics shares have traded in a compressed range near $0.68 in recent sessions, with a market capitalization around $65 million. The stock has been under sustained pressure through 2026, down roughly 45% year to date, as investors weigh an advancing but still unfunded late-stage pipeline against a modest cash balance. Sentiment has improved from deeply negative levels following the company's regulatory update, yet the share price has not staged a durable recovery, reflecting the uncertainty around how the pivotal trial will be financed. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Cognition Therapeutics (CGTX) Business Overview and Competitive Position
Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Purchase, New York, focused on small-molecule therapies for age-related degenerative disorders of the central nervous system and retina. Its lead candidate, zervimesine (CT1812), is an investigational once-daily oral sigma-2 receptor modulator designed to protect neuronal synapses by preventing the binding of toxic oligomers of pathogenic proteins. The company is advancing zervimesine across dementia with Lewy bodies (DLB), Alzheimer's disease, geographic atrophy secondary to dry age-related macular degeneration, and Parkinson's disease. Backed by nearly $200 million in National Institutes of Health and related foundation grants, Cognition has built a diversified, grant-supported research program, though it has no product revenue as a pre-commercial-stage developer.
Recent Developments Driving CGTX
The most consequential recent event was the October 22, 2026 announcement that Cognition had aligned with the U.S. Food and Drug Administration on the design of a pivotal Phase 3 trial of zervimesine in mild-to-moderate DLB. The agreed design uses the NPI-2 (hallucinations and delusions) scale as the primary endpoint, ADCS-ADL as a key secondary endpoint, a 100 mg once-daily dose versus placebo over nine months, and patient enrichment for baseline psychosis. The company also indicated the FDA would consider a single pivotal trial as a basis for approval, a materially smaller and less costly path than the roughly $150 million trial previously contemplated.
Earlier in October, the U.S. Patent and Trademark Office granted Cognition a composition-of-matter patent covering a novel crystalline form of zervimesine with a natural expiration of 2045. On November 5, 2026, the company reported third-quarter results showing a net loss of $4.1 million and approximately $31.5 million in cash, plus $18.2 million in remaining obligated grant funds, extending its projected runway into the fourth quarter of 2027. H.C. Wainwright reiterated a Buy rating and a $3.00 price target following the patent grant.
2026 Outlook and What Investors Should Watch
Looking ahead, the dominant theme is execution on the newly aligned DLB Phase 3 program. Management has targeted a mid-2027 trial start, and investors will closely monitor how the company funds a pivotal study that remains unfinanced, with partnering discussions and potential dilution as the principal paths. A second major catalyst is the Phase 2 START study in early Alzheimer's disease, which is expected to deliver topline data in the second half of 2027, near the point when the current cash runway is projected to run thin. Analysts maintain a constructive consensus with price targets well above the current share price, but the stock remains exposed to binary clinical and financing outcomes, ongoing cash burn, and broader small-cap biotech volatility. From what I see, this is important because the financing question will likely dictate near-term direction.
Exploring Tickeron’s Trending AI Robots
In my view, tools like Tickeron’s platform can add a quantitative layer to fundamental research on names like CGTX. The Trending AI Robots page curates a focused selection of the platform's top-performing AI trading bots from among hundreds of automated strategies that monitor thousands of tickers. Each bot applies its own distinct approach, with variations in strategy type, trading timeframe, and performance metrics, so only the most relevant and currently strong performers surface in this section. The page is designed to help traders and investors identify quantitatively driven signals without needing to build models themselves. For those interested in data-backed trading ideas beyond fundamental analysis, the Trending AI Robots section offers a practical starting point.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CGTX's RSI Oscillator ascends from oversold territory
The RSI Indicator for CGTX moved out of oversold territory on November 06, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 34 similar instances when the indicator left oversold territory. In 31 of the 34 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 59 of 71 cases where CGTX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
The Moving Average Convergence Divergence (MACD) for CGTX just turned positive on November 06, 2026. Looking at past instances where CGTX's MACD turned positive, the stock continued to rise in 35 of 45 cases over the following month. The odds of a continued upward trend are 78%.
Following a +8.69% 3-day Advance, the price is estimated to grow further. Considering data from situations where CGTX advanced for three days, in 162 of 204 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
CGTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CGTX as a result. In 93 of 104 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CGTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for CGTX entered a downward trend on November 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 27 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.978) is normal, around the industry mean (3.498). P/E Ratio (-4.041) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 82 (best 1 - 100 worst), indicating slightly worse than average price growth. CGTX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CGTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement